ADMA Biologics Inc (ADMA)

Currency in USD
14.6600
+0.1300(+0.89%)
Closed·
14.6500-0.0100(-0.07%)
·
ADMA Scorecard
Full Analysis
Cash flows can sufficiently cover interest payments
ADMA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14.480014.8900
52 wk Range
13.500025.6700
Key Statistics
Prev. Close
14.53
Open
14.56
Day's Range
14.48-14.89
52 wk Range
13.5-25.67
Volume
2.98M
Average Volume (3m)
3.12M
1-Year Change
-27.75%
Book Value / Share
1.67
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ADMA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.0600
Upside
+98.23%
Members' Sentiments
Bearish
Bullish
ProTips
Liquid assets exceed short term obligations

ADMA Biologics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

ADMA Biologics Inc Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Employees
685

ADMA Biologics Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue reached $114.8M, up 40% YoY, beating forecasts; stock closed +2.03% but fell 4.49% after hours
  • Gross profit hit $61.1M with 53.2% margin; adjusted EBITDA rose 81% YoY to $47.9M; GAAP net income at $26.9M
  • FDA approved new production process to boost output; voluntary product withdrawals impacted Q1 revenue by $3.8M
  • 2025 guidance: $500M+ revenue, $235M+ adjusted EBITDA; 2026 forecast: $625M revenue, $340M+ adjusted EBITDA
  • CEO confident in future growth; analysts maintain bullish outlook with price targets ranging from $20.96 to $32.00
Last Updated: 07/05/2025, 22:28
Read Full Transcript

Compare ADMA to Peers and Sector

Metrics to compare
ADMA
Peers
Sector
Relationship
P/E Ratio
16.7x−0.8x−0.6x
PEG Ratio
0.04−0.020.00
Price/Book
8.8x0.7x2.6x
Price / LTM Sales
7.4x138.7x3.4x
Upside (Analyst Target)
111.5%262.3%35.5%
Fair Value Upside
Unlock6.4%3.7%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 29.0600
(+98.23% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
0.14 / 0.15
Revenue / Forecast
121.98M / 124.13M
EPS Revisions
Last 90 days

ADMA Income Statement

People Also Watch

200.74
ALAB
-4.23%
286.14
ORCL
-0.91%
175.59
LULU
-1.46%
257.20
IT
-0.01%

FAQ

What Stock Exchange Does ADMA Biologics Inc Trade On?

ADMA Biologics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for ADMA Biologics Inc?

The stock symbol for ADMA Biologics Inc is "ADMA."

What Is the ADMA Biologics Inc Market Cap?

As of today, ADMA Biologics Inc market cap is 3.50B.

What Is ADMA Biologics Inc's Earnings Per Share (TTM)?

The ADMA Biologics Inc EPS (TTM) is 0.85.

When Is the Next ADMA Biologics Inc Earnings Date?

ADMA Biologics Inc will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is ADMA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has ADMA Biologics Inc Stock Split?

ADMA Biologics Inc has split 0 times.

How Many Employees Does ADMA Biologics Inc Have?

ADMA Biologics Inc has 685 employees.

What is the current trading status of ADMA Biologics Inc (ADMA)?

As of 05 Oct 2025, ADMA Biologics Inc (ADMA) is trading at a price of 14.6600, with a previous close of 14.53. The stock has fluctuated within a day range of 14.4800 to 14.8900, while its 52-week range spans from 13.5000 to 25.6700.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.